

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	4
-------	---	----	---

Complete if Known

Application Number	10/594,620
Filing Date	June 27, 2007
First Named Inventor	MOORE, Jonni
Art Unit	1656 1657
Examiner Name	Paul C. Martin
Attorney Docket Number	P-7671-US

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

/Paul Martin/

Date _____

**Date
Considered**

06/01/2009

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw the through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. This collection is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is required to take 2 hours to complete, including gathering, preparing, and submitting the information to the USPTO. Time varies depending upon the individual case. Any comments on the information collection may require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.M./

PTO/5B/09b (07-06)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/594,620
				Filing Date	June 27, 2007
				First Named Inventor	MOORE, Jonni
				Art Unit	1666 1057
				Examiner Name	Paul C. Martin
Sheet	2	of	4	Attorney Docket Number	P-7671-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	B	AMICOSANTE M, et al. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69. Hum Immunol 2001;82:686-693.	
	C	APPAY V, et al. Characterization of CD4(b) CTLs ex vivo. J Immunol 2002;168:5954-5958.	
	D	BARNA BP et al. Clinical application to Beryllium Lymphocyte Proliferation Testing. Clin Diagn Lab Immunol 2003;10:990-994.	
	E	BARTELL SM, et al. Risk estimation and value-of-information analysis for three proposed genetic screening programs for chronic beryllium disease prevention. Risk Anal 2000;20:87-99.	
	F	BERNARD S, et al. Analysis of cell kinetics using a cell division marker: Mathematical modeling of experimental data. Biophys J 2003;84:3414-3424.	
	G	BILL JR, et al. Beryllium presentation to CD4p T cells is dependent on a single amino acid residue of the MHC class II beta-chain. J Immunol 2005;175:7029-7037.	
	H	DEUBNER D, et al. Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility. Appl Occup Environ Hyg 2001;16:579-592.	
	I	DEUBNER DC, et al. Variability, predictive value, and uses of the beryllium blood lymphocyte proliferation test (BLPT): Preliminary analysis of the ongoing workforce survey. Appl Occup Environ Hyg 2001;16:521-526.	
	J	FARRIS GM, et al. Detection of Beryllium sensitivity using a flow cytometric lymphocyte proliferation test The Immuno-Be-LPT. Toxicology 2000;143:125-140.	
	K	FONTENOT AP, et al. Frequency of beryllium-specific, central memory CD4p T cells in blood determines proliferative response. J Clin Invest 2005;115:2886-2893.	
	L	GVAN AL, et al. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J Immunol Methods 1999;230:99-112.	
	M	HENNEBERGER PK, et al. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health 2001;74:167-176.	
	N	HENNEBERGER PK, et al. Industries in the United States with airborne beryllium exposure and estimates of the numbers of current workers potentially exposed. J Occup Environ Hyg 2004;1:648-659.	
	O	JANEWAY CA Jr, et al. CD4p T cells: Specificity and function. Immunol Rev 1988;101:39-80.	
	P	KREISS K, et al. Chronic beryllium disease—From the workplace to cellular immunology, molecular immunogenetics, and back. Clin Immunol Immunopathol 1994;71:123-129.	
	Q	KREISS K, et al. Screening blood test identifies subclinical beryllium disease. J Occup Med 1989;31:603-608.	

Examiner Signature	/Paul Martin/	Date Considered	06/01/2009
--------------------	---------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 127 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/08b (07-05)

Approved for use through 06/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/594,620		
		Filing Date	June 27, 2007		
		First Named Inventor	MOORE, Jonni		
		Art Unit	1656 1657		
		Examiner Name	Paul C. Martin		
Sheet	3	of	4	Attorney Docket Number	P-7671-US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
R		LEHNERT NM, et al. Inhibition of normal human lung fibroblast growth by beryllium. Toxicology 2001;160:119-127.	
S		LYONS AB, Hasboid J, Hodgkin PD. Flow cytometric analysis of cell division history using dilution of carboxyfluorescein diacetate succinimidyl ester, a stably integrated fluorescent probe. Methods Cell Biol 2001;63:375-398.	
T		LYONS AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods 2000;243:147-154.	
U		LYONS AB. Divided we stand: Tracking cell proliferation with carboxyfluorescein diacetate succinimidyl ester. Immunol Cell Biol 1999;77:509-515.	
V		MAIER LA. Beryllium health effects in the era of the beryllium lymphocyte proliferation test. Appl Occup Environ Hyg 2001;16:514-520.	
W		MAIER LA. Clinical approach to chronic beryllium disease and other non pneumoconiotic interstitial lung diseases. J Thorac Imaging 2002;17:273-284.	
X		MAIER LA. Genetic and exposure risks for chronic beryllium disease. Clin Chest Med 2002;23:827-839.	
Y		MCCANLIES EC, et al.HLA-DPB1 and chronic beryllium disease: A HuGE review. Am J Epidemiol 2003;157:388-398.	
Z		MILLOVANOVA T, et al.Flow Cytometric Test for Beryllium Sensitivity. Cytometry part B Clinical Cytometry 2004;60:23-30.	
AA		NEWMAN LS. Significance of the blood beryllium lymphocyte proliferation test. Environ Health Perspect 1996;104 (Suppl 5):953-956.	
AB		NIKOLAEVA N, et al. Differentiation of human alloreactive CD4p and CD8p T cells invitro. Transplantation 2004;78:815-824.	
AC		ROSSMAN MD, et al. Proliferative response of bronchoalveolar lymphocytes to beryllium. A test for chronic beryllium disease. Ann Intern Med 1988;108:687-693.	
AD		ROSSMAN MD. Chronic beryllium disease: Diagnosis and management. Environ Health Perspect 1996;104 (Suppl 5):945-947.	
AE		ROSSMAN MD. Chronic beryllium disease: A hypersensitivity disorder. Appl Occup Environ Hyg 2001;16:615-618.	
AF		SALTINI C, et al. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N Engl J Med. 1989;320:1103-1109.	
AG		SAWYER RT, et al. Beryllium-induced TNF- α production by CD4p T Cells is mediated by HLA-DP. Am J Respir Cell Mol Biol 2004;31:122-130.	
AH		SPITZER RL, et al. Quantification of agreement in psychiatric diagnosis. A new approach. Arch Gen Psychiatry 1967;17:83-87.	
AI		STANGE AW, et al. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl Occup Environ Hyg 2001;16:405-417.	

Examiner Signature	/Paul Martin/	Date Considered	06/01/2009
--------------------	---------------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Applicant's unique citation designation number (optional). ‡ Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.59. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

